Genetic variants in the MRPS30 region and postmenopausal breast cancer risk

Table 2 Significance levels (P-values) for testing interaction with WHI trial interventions for SNPs in the MRPS30 region

Rs number^a	Chromosome	Position	Minor/major allele	MAF^b	OR^c	p.main^d	E-alone^e	E+P^f	DMQ^g	CaD^h
7705343	5p12	44915334	G/A	0.40	1.18	0.000355	0.043	0.863	0.042	0.046
13159598	5p12	44841683	G/A	0.41	1.17	0.000425	0.056	0.920	0.057	0.048
11746980	5p12	44813635	A/G	0.41	1.16	0.000511	0.064	0.790	0.043	0.095
9790879	5p12	44935642	C/T	0.41	1.17	0.000963	0.117	0.762	0.042	0.047
2330572	5p12	44776746	C/A	0.42	1.16	0.00129	0.042	0.880	0.043	0.106
4415084	5p12	44698272	T/C	0.41	1.17	0.000436	0.242	0.944	0.127	0.146
994793	5p12	44779004	G/A	0.42	1.15	0.00184	0.084	0.798	0.041	0.080
2218080	5p12	44750087	C/T	0.43	1.15	0.00274	0.273	0.933	0.025	0.069

^aRs number, SNP identification (rs) number in dbSNP database; ^bMAF, minor allele frequency in the study population; ^cOR, estimated minor allele odds ratio under additive allelic effects model; ^dp.main, significance level for SNP association with breast cancer in additive allele effects model; ^eE-alone, P-value for dependence (interaction) of E-alone odds ratio on SNP from case-only analyses; ^fE+P and ^hCaD, corresponding interaction P-values for the other interventions; ^gDMQ, interaction P-value for DM among women with baseline percentage energy from fat in the upper quartile. Entries in bold are interaction effects significant at the nominal (0.05) level. WHI, Women's Health Initiative.

ISSN: 1756-994X